Semax: FDA status, legal access, dosage and side effects
What the peptide is, what changed in October 2026, and what the research does and does not show.
Semax is a synthetic seven-amino-acid peptide, Met-Glu-His-Phe-Pro-Gly-Pro, built on a fragment of the pituitary hormone ACTH and studied mostly in Russia, where it is used for ischemic stroke. It is not FDA-approved. Since October 30, 2026, an interim HHS policy lets 503A pharmacies compound it as a nasal product by prescription. REMEVi does not currently offer Semax.
Semax is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer Semax.
What changed in 2026
On October 30, 2026, the Federal Register published notice of HHS’s interim enforcement-discretion policy for 503A compounding (Federal Register, October 30, 2026). HHS said it does not intend to take enforcement action against a state-licensed pharmacy or federal facility that compounds a drug from one of six listed peptides, Semax among them, while the 503A bulks list is developed through rulemaking.
For Semax, the policy’s appendix lists Semax free base, intranasal. Every condition below must be met:
- A patient-specific prescription from a licensed prescriber.
- Compounding by a state-licensed 503A pharmacy (503B outsourcing facilities are not covered).
- The peptide and route match the appendix: for Semax, the free base, given intranasally. Injected Semax is outside the policy.
- Bulk substance from an FDA-registered facility with a valid certificate of analysis (CoA); the original manufacturer is FDA-registered and CGMP-compliant.
- A single active ingredient per product: no combination products, including Semax with Selank.
- No device other than an FDA 510(k)-cleared syringe packaged with or containing the drug.
- The label reads “This is a compounded drug product. Not for resale.”
- Serious adverse events are reported to FDA MedWatch.
The policy is interim, non-binding and revocable: HHS may revisit it if a safety signal or product quality issue arises. It is not FDA approval and does not add Semax to the 503A bulks list. Public comments were open for two weeks after October 30 (docket HHS-OASH-2026-0496).
Read the Federal Register notice · The 2026 HHS peptide policy, explained
How a legal Semax prescription works
- A licensed provider evaluates you and decides whether Semax is appropriate. Many will not prescribe it, given how little human data exists outside Russian studies.
- If they do, they write a prescription for you by name: a patient-specific prescription, not an office-stock order.
- A state-licensed 503A compounding pharmacy prepares a nasal product from Semax free base, from a registered, CoA-documented bulk source, as a single-ingredient product.
- The product arrives labelled “This is a compounded drug product. Not for resale.” Any serious adverse event is reported to FDA MedWatch.
REMEVi does not currently offer Semax, so REMEVi does not take part in any step of this path for it.
Research-grade vials and sprays vs compounded prescriptions
Semax vials and nasal sprays sold online “for research use” are not compounded prescriptions and sit outside the HHS policy. They are not prepared for a named patient, not dispensed by a licensed pharmacy, and carry no requirement for a registered bulk source, a certificate of analysis or MedWatch reporting.
The appendix names Semax free base. A product labelled as a different form, such as N-acetyl Semax amidate, does not match that listed identity. On August 24, 2026, FDA sent warning letters to five online peptide vendors; per Holland & Knight, “research use” labels did not outweigh evidence that the products were meant for people.
What research exists on Semax
Nearly all Semax research comes from Russian groups, and much of it is published in Russian with English abstracts. A 2022 review of peptide drugs developed in Russia lists Semax as a nootropic drug used to treat ischemic stroke. There are small human studies, but no large randomized, placebo-controlled trial we could find, and little human outcome data.
- Stroke: a 2018 study of 110 people after ischemic stroke measured blood BDNF (a nerve growth factor) and rehabilitation scores; the abstract does not describe randomization or a placebo.
- Motor neuron disease: a 2007 open-label study of 27 patients found no change in the course of nerve damage; the authors reported a higher quality-of-life score.
- Optic nerve disease: a 2000 Russian study added Semax nasal drops to standard treatment in a controlled comparison.
- Animal studies: rat studies have measured BDNF and other nerve growth factor genes after intranasal Semax; animal findings do not show what happens in people.
Semax was one of the six peptides FDA’s advisory committee voted to recommend in July 2026; that vote was advisory and is not FDA approval.
Semax side effects: summary
The Russian studies we could open report few or no adverse effects, but most abstracts do not describe how side effects were collected, and no independent safety trial exists. Nasal irritation is possible with any nasal product. Long-term effects are unknown.
Semax dosage: summary
Published Russian studies gave Semax intranasally in short courses, usually 10 days, sometimes repeated after a break. Amounts differ by condition and solution strength. Published protocols vary; a licensed provider sets your dose; never self-dose.
Semax cost: summary
Published prices for prescribed Semax vary by channel, from telehealth listings to clinic programs that bundle the visit and follow-up; most were posted before the October 2026 policy. Research-grade products list for less because they skip the prescription, pharmacy and quality steps. REMEVi does not currently price Semax.
Is Semax legal in the US?
Semax is not FDA-approved. Since October 30, 2026, HHS’s interim policy says it will not take enforcement action when a state-licensed 503A pharmacy compounds Semax free base as a nasal product on a patient-specific prescription and meets every listed condition. The policy is non-binding and revocable, and it does not cover research-labelled products.
Do you need a prescription for Semax?
Yes, for a compounded product covered by the HHS policy. The policy requires a patient-specific prescription from a licensed prescriber, filled by a state-licensed 503A pharmacy. Semax sprays and vials sold without a prescription as research chemicals are outside the policy and are not compounded prescriptions, whatever their label says.
What is Semax used for?
In the US, Semax is not FDA-approved for any use. In Russia, a 2022 review describes it as a nootropic drug used to treat ischemic stroke, and Russian studies have examined it in stroke rehabilitation, optic nerve disease and motor neuron disease. Those studies are small, and independent trials outside Russia are lacking.
Is N-acetyl Semax the same as Semax?
No. N-acetyl Semax amidate is a chemically modified form, and HHS’s policy appendix names Semax free base for intranasal use. Under the policy, a covered product must have the identity and route stated in the appendix, so a different form does not match it. The published studies cited on this page describe Semax itself.
More questions
Does REMEVi offer Semax?
No. REMEVi does not currently offer Semax. REMEVi prescribes NAD+, sermorelin and GLP-1 treatment through licensed pharmacies; those pages are linked below.
Can Semax be injected under the policy?
No. HHS’s policy lists Semax for intranasal use. Injected Semax does not match the listed route, so it falls outside the policy.
Sources
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, 91 FR 68526 (Federal Register, October 30, 2026) (read November 2, 2026)
- Foley & Lardner, National Law Review 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Nutritional Outlook 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
- AJMC 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
- Holland & Knight 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
- Deigin et al., Pharmaceutics 2022 — Development of peptide biopharmaceuticals in Russia (read November 2, 2026)
- Gusev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2018 — The efficacy of semax in the treatment of patients at different stages of ischemic stroke (read November 2, 2026)
- Serdiuk et al., Zh Nevrol Psikhiatr Im S S Korsakova 2007 — Chronic partial denervation and quality of life in patients with motor neuron disease treated with semax (read November 2, 2026)
- Polunin et al., Vestn Oftalmol 2000 — Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease (read November 2, 2026)
- Dolotov et al., Brain Res 2006 — Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus (read November 2, 2026)
- Agapova et al., Neurosci Lett 2007 — Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10 (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·